<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87288</article-id><article-id pub-id-type="doi">10.7554/eLife.87288</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87288.4</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-308680"><name><surname>Yanagihara</surname><given-names>Toyoshi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2212-0631</contrib-id><email>toyoshi.yana@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-308715"><name><surname>Hata</surname><given-names>Kentaro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0001-9353-8381</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308716"><name><surname>Matsubara</surname><given-names>Keisuke</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308717"><name><surname>Kunimura</surname><given-names>Kazufumi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3445-804X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-353021"><name><surname>Suzuki</surname><given-names>Kunihiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308719"><name><surname>Tsubouchi</surname><given-names>Kazuya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308720"><name><surname>Ikegame</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308721"><name><surname>Baba</surname><given-names>Yoshihiro</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-119358"><name><surname>Fukui</surname><given-names>Yoshinori</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308722"><name><surname>Okamoto</surname><given-names>Isamu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vv7qz60</institution-id><institution>Department of Respiratory Medicine, NHO Fukuoka National Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Division of Immunology and Genome Biology, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><p><sup>†</sup>These authors contributed equally to this work and share the first authorship</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>04</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP87288</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-17"><day>17</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-02-21"><day>21</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.21.529383"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-06-08"><day>08</day><month>06</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87288.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-25"><day>25</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87288.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-14"><day>14</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87288.3"/></event></pub-history><permissions><copyright-statement>© 2023, Yanagihara, Hata et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Yanagihara, Hata et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87288-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87288-figures-v1.pdf"/><abstract><p>Anticancer treatments can result in various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity in the lung. One of the major opportunistic infections is <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), which can cause severe respiratory complications and high mortality rates. Cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs). Nonetheless, the differentiation of these diseases can be difficult, and the pathogenic mechanisms of such diseases are not yet fully understood. To better comprehend the immunophenotypes, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with PCP, cytotoxic drug-induced ILD (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers. In PCP, we observed an expansion of the CD16<sup>+</sup> T cell population, with the highest CD16<sup>+</sup> T proportion in a fatal case. In ICI-ILD, we found an increase in CD57<sup>+</sup> CD8<sup>+</sup> T cells expressing immune checkpoints (TIGIT<sup>+</sup> LAG3<sup>+</sup> TIM-3<sup>+</sup> PD-1<sup>+</sup>), FCRL5<sup>+</sup> B cells, and CCR2<sup>+</sup> CCR5<sup>+</sup> CD14<sup>+</sup> monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mass cytometry</kwd><kwd><italic>Pneumocystis jirovecii</italic> pneumonia</kwd><kwd>immune-checkpoint inhibitor</kwd><kwd>bronchoalveolar lavage fluid</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>The Kakihara Foundation</institution></institution-wrap></funding-source><award-id>4-9-10</award-id><principal-award-recipient><name><surname>Yanagihara</surname><given-names>Toyoshi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100017346</institution-id><institution>Boehringer Ingelheim Japan</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yanagihara</surname><given-names>Toyoshi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fukui</surname><given-names>Yoshinori</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Increased CD16<sup>+</sup> T cell populations in bronchoalveolar lavage fluid highlight a potential biomarker and immune response mechanism in <italic>Pneumocystis jirovecii</italic> pneumonia.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The advancements in anticancer therapy have revolutionized cancer management and have led to improved patient outcomes. However, these therapies can also lead to various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity, with the lungs being a commonly affected organ (<xref ref-type="bibr" rid="bib9">Conte et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Morelli et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">Skeoch et al., 2018</xref>). One of the major opportunistic infections in cancer patients or those receiving immunosuppressive treatment is <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), which can cause severe respiratory complications and high mortality rates (<xref ref-type="bibr" rid="bib34">Thomas and Limper, 2004</xref>; <xref ref-type="bibr" rid="bib3">Asai et al., 2022</xref>; <xref ref-type="bibr" rid="bib2">Apostolopoulou and Fishman, 2022</xref>). However, the precise immune reactions during PCP development and mechanisms of lung injury remain largely unknown.</p><p>While both cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs), the mechanisms underlying these complications may differ between the two classes of drugs. In particular, ICI-associated ILDs are considered a type of immune-related adverse events (irAEs) (<xref ref-type="bibr" rid="bib25">Postow et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Ando et al., 2021</xref>). Nonetheless, the precise mechanisms that cause drug-induced ILDs are predominantly unidentified. Further, despite various diagnostic approaches, including radiology and molecular testing, there is a need for useful biomarkers to distinguish PCP, cytotoxic drug-induced (DI)-ILD, and ICI-ILD.</p><p>Mass cytometry, also known as cytometry by time-of-flight (CyTOF), is a cutting-edge technology that uses inductively coupled plasma mass spectrometry to detect metal ions tagged to antibodies that bind to specific cellular proteins, allowing for a detailed and multidimensional characterization of cellular composition and function (<xref ref-type="bibr" rid="bib30">Spitzer and Nolan, 2016</xref>). This technique provides a unique advantage over traditional flow cytometry, which is limited by spectral overlap and the number of parameters that can be analyzed simultaneously. Mass cytometry has been used to study a variety of biological systems, including immune-mediated diseases, such as cancer and autoimmune conditions (<xref ref-type="bibr" rid="bib21">Matsubara et al., 2021</xref>; <xref ref-type="bibr" rid="bib17">Hata et al., 2023</xref>; <xref ref-type="bibr" rid="bib10">Couloume et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Chedid et al., 2022</xref>). Through high-throughput analysis of large numbers of single cells, mass cytometry can provide a more comprehensive understanding of the cellular heterogeneity and signaling pathways involved in these diseases, allowing for the identification of potential therapeutic targets and biomarkers.</p><p>This study aims to distinguish pulmonary involvement in patients with malignancy undergoing chemotherapy and identify potential biomarkers for DI-ILD, ICI-ILD, and PCP by analyzing bronchoalveolar lavage fluid (BALF) samples with mass cytometry. By characterizing the cellular and molecular changes in BALF from patients with these complications, we aim to improve our understanding of their pathogenesis and identify potential therapeutic targets.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Patient characteristics and clinical parameters</title><p>We analyzed seven cases of PCP, nine of DI-ILD, and nine of ICI-ILD (<xref ref-type="table" rid="table1">Table 1</xref>). One of the PCP cases was fatal. Differential cell counts for BALF revealed lymphocytosis in seven out of seven cases (100%) of PCP as well as in eight out of nine cases (88.9%) of DI-ILD and seven out of nine cases (63.6%) of ICI-ILD when the cutoff for the percentage of lymphocytes was set to &gt;20%. Serum levels of β-<sc>d</sc>-glucan were significantly higher in patients with PCP than those with DI-ILD or ICI-ILD (196.5 ± 419.8, 3.7 ± 7.1, 0.6 ± 1.4 pg/mL, respectively) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic utility of β-<sc>d</sc>-glucan for PCP, with values from the DI-ILD group used as a reference (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The area under the curve was determined to be 0.8929. When the cutoff value was set to 14.70 pg/mL, the sensitivity and specificity of PCP were 85.71 and 87.50%, and the positive likelihood ratio was 6.86. The diagnostic value of β-<sc>d</sc>-glucan was consistent with the previous study (<xref ref-type="bibr" rid="bib33">Tasaka et al., 2007</xref>), where the positive likelihood ratio was 6.57, with a cutoff value of 31.0. The serum levels of KL-6, an indicator of various types of interstitial pneumonitis (<xref ref-type="bibr" rid="bib18">Ishikawa et al., 2012</xref>), tended to be higher in patients with ICI-ILD than PCP or DI-ILD, though insignificant (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Four out of seven (57.1%) in PCP, one out of nine (11.1%) in DI-ILD, and six out of nine (66.7%) in ICI-ILD were positive for KL-6 with a cutoff value of 500 U/mL.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Serum levels of β-<sc>d</sc>-glucan and KL-6 from patients with <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title><p>(<bold>A</bold>) Serum levels of β-<sc>d</sc>-glucan from patients with PCP, DI-ILD, and ICI-ILD. (<bold>B</bold>) A receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic utility of β-<sc>d</sc>-glucan for PCP, with values from the DI-ILD group used as a reference. The area under the curve was determined to be 0.8929. (<bold>C</bold>) Serum levels of KL-6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig1-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of the study population.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">PCP</th><th align="left" valign="bottom">DI-ILD</th><th align="left" valign="bottom">ICI-ILD</th></tr></thead><tbody><tr><td align="left" valign="bottom">Number</td><td align="left" valign="bottom">7</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">9</td></tr><tr><td align="left" valign="bottom">Age</td><td align="left" valign="bottom">66.9 ± 4.6</td><td align="left" valign="bottom">58.8 ± 19.3</td><td align="left" valign="bottom">71.9 ± 4.5</td></tr><tr><td align="left" valign="bottom">Male % (n)</td><td align="left" valign="bottom">42.8 (3)</td><td align="left" valign="bottom">77.8 (7)</td><td align="left" valign="bottom">100 (9)</td></tr><tr><td align="left" valign="bottom">Suspected drug/regimen</td><td align="left" valign="bottom"/><td align="left" valign="bottom">VAC (2), FOLFIRI (2), DTX (1), AC (1), GEM (1), TS-1 (1), BEP (1)</td><td align="left" valign="bottom">Nivolumab (3), pembrolizumab (3), durvalmab (2), atezolizumab (1)</td></tr><tr><td align="left" valign="bottom">CTCAE grade</td><td align="left" valign="bottom">G2 (5), G3 (1), G5 (1)</td><td align="left" valign="bottom">G1 (2), G2 (7)</td><td align="left" valign="bottom">G2 (7), G3 (2)</td></tr><tr><td align="left" valign="bottom" colspan="4"><italic>BALF cell differentiation (%)</italic></td></tr><tr><td align="left" valign="bottom">Macrophage</td><td align="left" valign="bottom">25 ± 8.9</td><td align="left" valign="bottom">40.2 ± 23.5</td><td align="left" valign="bottom">44.4 ± 26.6</td></tr><tr><td align="left" valign="bottom">Neutrophil</td><td align="left" valign="bottom">13.6 ± 29.7</td><td align="left" valign="bottom">1.9 ± 1.3</td><td align="left" valign="bottom">14.4 ± 26.7</td></tr><tr><td align="left" valign="bottom">Lymphocyte</td><td align="left" valign="bottom">58.8 ± 30.5</td><td align="left" valign="bottom">56.2 ± 24.8</td><td align="left" valign="bottom">35.6 ± 23.7</td></tr><tr><td align="left" valign="bottom">Eosinophil</td><td align="left" valign="bottom">0.9 ± 1.1</td><td align="left" valign="bottom">1.7 ± 1.9</td><td align="left" valign="bottom">5.6 ± 8.5</td></tr></tbody></table><table-wrap-foot><fn><p>Data for age and BALF analysis are presented as means ± SD.</p></fn><fn><p>PCP = <italic>Pneumocystis jirovecii</italic> pneumonia; DI-ILD = cytotoxic drug-related interstitial lung disease; ICI-ILD = immune-checkpoint inhibitor-related ILD; BALF = bronchoalveolar lavage fluid; VAC = vincristine, actinomycin D, and cyclophosphamide; FOLFIRI = folinic acid, fluorouracil, and irinotecan hydrochloride; DTX = docetaxel; AC = adriamycin and cyclophosphamide; GEM = gemcitabine; TS-1 = tegafur gimeracil oteracil potassium; BEP = bleomycin, etoposide, and platinum; CTCAE = Common Terminology Criteria evaluated the severity of the disease for Adverse Events grading; grade 1 = asymptomatic; grade 2 = symptomatic; grade 3 = severe symptoms, requiring oxygen therapy; grade 4 = life-threatening respiratory failure; grade 5 = death.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Expansion of CD16<sup>+</sup> T cells in BALF from patients with PCP</title><p>First, we investigated whether subsets of T cells (gated CD2<sup>+</sup> CD3<sup>+</sup>) differentially existed in PCP, DI-ILD, and ICI-ILD with mass cytometry. T cell lymphocytosis was observed in all groups (PCP: 62.9 ± 17.5%; DI-ILD: 58.3 ± 24.5%; ICI-ILD: 50.4 ± 29.9%) with a higher tendency of CD4/CD8 ratio observed in DI-ILD compared to PCP and ICI-ILD (PCP: 1.13 ± 0.86; DI-ILD: 6.08 ± 6.06; ICI-ILD: 1.9 ± 1.40) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To visualize T cell differentiation within the affected lungs, we generated Uniform Manifold Approximation and Projection (UMAP) plots (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The majority of T cells in the BALF displayed either memory or effector phenotypes, with a limited population of naïve T cells (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). Specifically, we observed a tendency of a higher abundance of transient memory/effector memory CD4 T cells and a lower abundance of transient memory/effector memory CD45RA (EMRA) CD8 T cells in DI-ILD compared to the other two groups (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Characterization of T cell subsets in bronchoalveolar lavage fluid (BALF) from patients with <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title><p>(<bold>A</bold>) Percentage of T cells (defined as CD2<sup>+</sup>CD3<sup>+</sup>) in CD45<sup>+</sup> BALF cells and CD4/CD8 ratio in T cells from patients with PCP, DI-ILD, and ICI-ILD. (<bold>B</bold>) Uniform Manifold Approximation and Projection (UMAP) of concatenated samples visualizing the distribution of T cell subpopulations. Central memory (CM) T cells were defined by CCR7<sup>+</sup> CD45RO<sup>+</sup> CD28<sup>+</sup> Fas<sup>+</sup>, transitional memory (TM) by CCR7<sup>–</sup> CD45RO<sup>+</sup> CD28<sup>+</sup> Fas<sup>+</sup>, effector memory (EM) by CCR7<sup>–</sup> CD45RO<sup>+</sup> CD28<sup>–</sup> Fas<sup>+</sup>, terminal effector (TE) by CCR7<sup>–</sup> CD45RO<sup>+/–</sup> Fas<sup>–</sup>, and effector memory RA (EMRA) by CCR7<sup>–</sup> CD45RO<sup>–</sup> CD45RA<sup>+</sup> Fas<sup>+/–</sup>. Arrows indicate the trajectory of T cell differentiation. DN: CD4<sup>–</sup> CD8<sup>–</sup> double negative; DP: CD4<sup>+</sup> CD8<sup>+</sup> double positive. (<bold>C</bold>) Percentage of T cell subpopulations. (<bold>D</bold>) Citrus network tree visualizing the hierarchical relationship of each marker between identified T cell populations gated by CD45<sup>+</sup>CD2<sup>+</sup> CD3<sup>+</sup> from PCP (n = 7), DI-ILD (n = 9), and ICI-ILD (n = 5). Clusters with significant differences are represented in red, and those without significant differences in blue. Circle size reflects the number of cells within a given cluster. (<bold>E</bold>) Citrus-generated violin plots for six representative and differentially regulated populations. Each cluster number (#) corresponds to the number shown in panel (<bold>D</bold>). (<bold>F</bold>) Heatmap demonstrates the expression of various markers in different clusters of T cells, as identified through the Citrus analysis. All differences in abundance were significant at a false discovery rate &lt; 0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>A T cell gate (CD2<sup>+</sup>CD3<sup>+</sup>) and Citrus analysis of T cell populations in bronchoalveolar lavage fluid (BALF) cells from <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title><p>(<bold>A</bold>) Representative dot plots demonstrating the gating strategy for identification of T cell populations within BALF samples from patients with Pneumocystis jirovecii pneumonia (PCP), drug-induced interstitial lung disease (DI-ILD), and immune checkpoint inhibitor-induced lung disease (ICI-ILD). (<bold>B</bold>) Density plots comparing the expression of programmed death-ligand 1 (PD-1) on T cells from patients treated with Nivolumab versus other ICIs. (<bold>C</bold>) Citrus analysis of T cell populations with each surface marker. (<bold>D</bold>) Box plots depicting the abundance of distinct T cell clusters identified across different patient groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>T cell marker expression on the Uniform Manifold Approximation and Projection (UMAP) in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig2-figsupp2-v1.tif"/></fig></fig-group><p>We then utilized the Citrus algorithm to classify T cell subpopulations with varying degrees of abundance in an unsupervised manner by analyzing 31 parameters (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>). Our analysis identified 30 clusters of T cells, of which 13 were significantly differentiated between the groups. Interestingly, clusters #26299, #26293, and #26278, characterized by CD8<sup>+</sup> T cells expressing CD16 (FcγRIIIa), and cluster #26286, characterized by CD4<sup>+</sup> T cells expressing CD16, were abundant in PCP compared to DI-ILD and ICI-ILD (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). These CD8<sup>+</sup> T cells expressing CD16 were also positive for HLA-DR and CXCR3 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) but negative for CD14, a marker for monocytes (median CD14 expression of these clusters: 0.0–0.1 vs. 7.4–9.5 in monocyte populations). Cluster #26303, prevalent in ICI-ILD, comprised CD8<sup>+</sup> CD57<sup>+</sup> TIGIT<sup>+</sup> LAG3<sup>+</sup> but CD16<sup>–</sup> subpopulation (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). These cells also expressed PD-1 and TIM-3, although the expression was lower than clusters #26299, #26293, and #26278. These CD8<sup>+</sup> T cells expressed CD45RA but no expression of CD45RO and CCR7, indicating EMRA phenotype. Cluster #26281, prevalent in DI-ILD, was marked by CD4<sup>+</sup> with low immune-checkpoint expression (PD-1, TIM-3, TIGIT, LAG3, PD-L1, PD-L2, and OX40; <xref ref-type="fig" rid="fig2">Figure 2E and F</xref>).</p></sec><sec id="s2-3"><title>Myeloid cell subpopulations in the lungs of PCP, DI-ILD, and ICI-ILD</title><p>Next, we investigated myeloid cell populations (identified as CD3<sup>–</sup> CD11b<sup>+</sup> CD11c<sup>+</sup>). We first conducted UMAP to see the major myeloid cell populations. The UMAP plot categorized four major subtypes: monocytes, CCR2<sup>+</sup> macrophages, alveolar macrophages, and dendritic cells, with no significant difference in PCP, DI-ILD, and ICI-ILD (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). We next utilized the Citrus algorithm to further investigate differently abundant myeloid cell subpopulations by analyzing 18 parameters. Our analysis identified 31 clusters of myeloid cells, of which 17 were significantly differentiated between the groups (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Clusters #8220, #8215, and #8195, prevalent in PCP, were comprised of CD11b<sup>hi</sup> CD11c<sup>hi</sup> CD64<sup>+</sup> CD206<sup>+</sup> alveolar macrophages with HLA-DR<sup>hi</sup> (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). Clusters #8219 and #8197, prevalent in ICI-ILD, were characterized by CD14<sup>+</sup> CCR2<sup>+</sup> CCR5<sup>+</sup> monocyte subpopulations (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). Clusters #8227, #8223, and #8208, prevalent in DI-ILD, were marked by CD11b<sup>lo</sup> CD11c<sup>lo</sup> CD64<sup>lo</sup> CCR5<sup>+</sup> subpopulations (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Characterization of myeloid cell subsets in bronchoalveolar lavage fluid (BALF) from patients with <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title><p>(<bold>A</bold>) Uniform Manifold Approximation and Projection (UMAP) of concatenated samples visualizing the distribution of myeloid cell subpopulations in CD3<sup>–</sup> CD11b<sup>+</sup> CD11c<sup>+</sup> gated myeloid cells in BALF from patients with PCP, DI-ILD, and ICI-ILD. Monocytes were defined by CD64<sup>+</sup> CD14<sup>+</sup>, CCR2<sup>+</sup> macrophages (Mp) by CD64<sup>+</sup> CD14<sup>–</sup> CCR2<sup>+</sup>, alveolar Mp by CD64<sup>+</sup> CD14<sup>–</sup>CCR2<sup>–</sup> CD206<sup>+</sup>, dendritic cells (DC) by CD64<sup>–</sup>CD14<sup>–</sup>CD206<sup>–</sup>CD11c<sup>+</sup> HLA-DR<sup>+</sup>, and unidentified subsets by CD64<sup>–</sup> CD11b<sup>+/–</sup> CD11c<sup>+/–</sup> CD14<sup>–</sup> CD206<sup>–</sup>. (<bold>B</bold>) Percentage of myeloid cell subpopulations in PCP (n = 7), DI-ILD (n = 9), and ICI-ILD (n = 9). Dot plots represent individual samples. (<bold>C</bold>) Citrus network tree visualizing the hierarchical relationship of each marker between identified myeloid cell populations gated by CD45<sup>+</sup> CD3<sup>–</sup> CD11b<sup>+</sup> CD11c<sup>+</sup> from PCP (n = 6), DI-ILD (n = 9), and ICI-ILD (n = 9). Clusters with significant differences are represented in red, and those without significant differences in blue. Circle size reflects the number of cells within a given cluster. (<bold>D</bold>) Citrus-generated violin plots for six representative and differentially regulated populations. Each cluster number (#) corresponds to the number shown in panel (<bold>C</bold>). All differences in abundance were significant at a false discovery rate &lt; 0.01. (<bold>E</bold>) Heatmap demonstrates the expression of various markers in different clusters of myeloid cells, as identified through the Citrus analysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The Citrus analysis of myeloid cell populations in bronchoalveolar lavage fluid (BALF) cells from <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Myeloid cell marker expression on the Uniform Manifold Approximation and Projection (UMAP) in <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>B cell subpopulations in the lungs of ILDs</title><p>In addition to T cells and myeloid cells, we sought to investigate whether there were differential representations of B cells in BALF from PCP, DI-ILD, and ICI-ILD. By utilizing CD45<sup>+</sup>CD3<sup>–</sup>CD64<sup>–</sup> and CD19<sup>+</sup> or CD138<sup>+</sup> as gating parameters, we were able to detect the presence of B cells and plasma cells. The frequency of B cells/plasma cells was found to be relatively higher in patients with PCP compared to the other two groups, although the proportion of B cells and plasma cells remained low in all groups. (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). A t-stochastic neighborhood embedding (t-SNE) analysis of 17 parameters among B cells/plasma cells revealed the presence of various B cell subpopulations, including IgD<sup>+</sup>-naïve B cells, IgM<sup>+</sup> B cells, IgG<sup>+</sup> B cells, IgA<sup>+</sup> B cells, plasmablasts, and plasma cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Although not significant, higher levels of IgG<sup>+</sup> B cells were observed in patients with PCP, while individuals with ICI-ILD exhibited a greater presence of plasma cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Previous research has suggested that FCRL5<sup>+</sup> B cells contribute to the pathogenesis of autoimmune disorders (<xref ref-type="bibr" rid="bib24">Owczarczyk et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Dement-Brown et al., 2012</xref>). Therefore, we investigated the frequency of these cells in our study and found that FCRL5<sup>+</sup> B cells were more abundant in patients with ICI-ILD compared to those with PCP and DI-ILD, suggesting these FCRL5<sup>+</sup> B cells may have a role in irAE (8.37 ± 6.74%, 1.37 ± 2.30%, 2.29 ± 3.81%, respectively) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Characterization of B cell subsets in bronchoalveolar lavage fluid (BALF) from patients with <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-related interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD).</title><p>(<bold>A</bold>) Percentages of B cells and plasma cells in CD45<sup>+</sup> BALF cells. (<bold>B</bold>) t-stochastic neighborhood embedding (t-SNE) plots of concatenated samples visualizing the distribution of B cell subpopulations in CD64<sup>–</sup>CD3<sup>–</sup> and CD19<sup>+</sup> or CD138<sup>+</sup> gated B cells in BALF from patients with PCP, DI-ILD, and ICI-ILD. Naive B cells are defined by CD19<sup>+</sup>IgD<sup>+</sup>, IgM B cells: CD19<sup>+</sup> IgM<sup>+</sup>, IgG B cells: CD19<sup>+</sup> IgG<sup>+</sup>, IgA B cells: CD19<sup>+</sup> IgA<sup>+</sup>, plasmablasts: CD19<sup>+</sup> CD27<sup>+</sup> CD38<sup>+</sup> CD138<sup>–</sup>, plasma cells: CD19<sup>–</sup> CD138<sup>+</sup> and IgG<sup>+</sup> or IgA<sup>+</sup>. (<bold>C</bold>) Percentages of B cell subpopulations in PCP (n = 7), DI-ILD (n = 9), and ICI-ILD (n = 9). Dot plots represent individual samples. (<bold>D</bold>) Two-dimensional dot plots depicting FCRL5-expressing B cells within a gated population of B cells defined as CD64<sup>–</sup>CD3<sup>–</sup> and CD19<sup>+</sup> or CD138<sup>+</sup>. Percentages of FCRL5-expressing B cells within the total B cell population are also shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>B cell marker expression on the t-stochastic neighborhood embedding (t-SNE) projection in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Marked CD16<sup>+</sup> T cell expansion in BALF from a fatal case of PCP</title><p>One case of PCP that developed during the use of immunosuppressive drugs after living donor liver transplantation had a fatal course despite intensive treatment. Upon admission, chest CT images revealed the emergence of diffuse ground glass opacities and infiltration in the bilateral lungs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The serum levels of β-<sc>d</sc>-glucan and KL-6 were highly elevated (1146 pg/mL and 1561 U/mL, respectively). The T cell percentage was 51.3%, and the CD4/CD8 ratio was 0.58, which was not particularly different from other PCP cases (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Strikingly, 97.5% of T cells expressed CD16 in the BALF from the fatal case (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Further, not only the proportion but the CD16 intensity was the highest in the fatal case among PCP cases (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). On the contrary, there did not appear to be any significant differences in myeloid cell fractions, and CD16 expression was not particularly high in the fatal case (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). The correlation matrix of clinical parameters and mass cytometry parameters revealed that CD16 intensity in T cells may be correlated with disease severity (<italic>r</italic> = 0.748, p=0.053) and β-<sc>d</sc>-glucan (<italic>r</italic> = 0.868, p=0.011) (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Therefore, CD16 expression in T cells is not only a characteristic of PCP but also a potential indicator of disease severity. For reference, we investigated CD16 expression in BALF T cells from healthy controls along with severe COVID-19 patients using the publicly available single-cell RNA-sequencing data (GSE145926). In the BALF of healthy controls, <italic>FCGR3A</italic> (CD16) expression was observed in 18.7% of CD4<sup>+</sup> T cells and 7.22% of CD8<sup>+</sup> T cells in healthy controls. In contrast, severe COVID-19 patients exhibited expression rates of 17.2% in CD4<sup>+</sup> T cells and 22.1% in CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). Notably, CD8<sup>+</sup> T cells from COVID-19 patients showed significantly higher <italic>FCGR3A</italic> (CD16) expression compared to those from healthy controls (0.31 ± 0.62 vs 0.12 ± 0.43, p=2.47e-08), while no significant difference was observed in CD4<sup>+</sup> T cells between the two groups (0.22 ± 0.53 vs 0.34 ± 0.73, p=0.407).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Immunological phenotypes in a fatal case of <italic>Pneumocystis jirovecii</italic> pneumonia (PCP).</title><p>(<bold>A</bold>) Chest computed tomography images of the patient upon admission reveal the emergence of bilateral diffuse ground glass opacities and infiltration in both lungs. (<bold>B</bold>) Comparison of T cell percentage and CD4/CD8 ratio between a fatal case and surviving cases of PCP. (<bold>C</bold>) t-stochastic neighborhood embedding (t-SNE) plots illustrating the distribution of T cell subpopulations in bronchoalveolar lavage fluid (BALF) T cells (gated as CD45<sup>+</sup>CD2<sup>+</sup>CD3<sup>+</sup>) from a fatal case and surviving cases of PCP. Double-negative (DN) T cells were defined as CD4<sup>–</sup>CD8<sup>–</sup> T cells. (<bold>D</bold>) Percentages of each T cell subpopulation. Red dots represent the value of the fatal case. (<bold>E</bold>) Mean CD16 intensity in the T cell population. (<bold>F</bold>) Mean CD16 intensity in the myeloid cell population. (<bold>G</bold>) The correlation matrix in PCP cases. Pearson <italic>r</italic> values are shown in each square. (<bold>H</bold>) Violin plots illustrate <italic>FCGR3A</italic> (CD16) expression intensity on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, with each dot representing an individual cell in BALF from healthy controls (HCs) and COVID-19 patients, derived from single-cell RNA-seq dataset GSE145926. The significance of differences was assessed using the Wilcoxon test. ns: not significant, ***p&lt;0.001. (<bold>I</bold>) The proportion of <italic>FCGR3A</italic> (CD16)-positive cells within the CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations in BALF from HC and COVID-19 patients, with the <italic>FCGR3A</italic> expression threshold set at 0.5.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The correlation matrix with the CTCAE and intensity of each T cell markers in <italic>Pneumocystis jirovecii</italic> pneumonia (PCP) cases.</title><p>The correlation was calculated using the Pearson correlation coefficient. This involved correlating the CTCAE grade directly with the mean expression levels of each marker. The computations were conducted using GraphPad Prism version 9. CCR7, CD7, and CD57 are correlated with the severity (CTCAE) of PCP (p-values: 0.009, 0.035, and 0.039, respectively).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig5-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we have demonstrated the characteristic immune cell subpopulations present in BALF from patients with PCP, DI-ILD, and ICI-ILD. Our analysis revealed an expansion of CD16<sup>+</sup> T cells in patients with PCP, an increase in CD57<sup>+</sup> CD8<sup>+</sup> T cells expressing immune checkpoints, and FCRL5<sup>+</sup> B cells in ICI-ILD.</p><p>CD16 is a low-affinity Fc receptor (FcγRIIIa) for IgG, commonly expressed on NK cells as well as on neutrophils and monocytes (<xref ref-type="bibr" rid="bib26">Ravetch and Bolland, 2001</xref>), with only a small fraction of T cells expressing CD16 in healthy peripheral blood (<xref ref-type="bibr" rid="bib28">Sandor and Lynch, 1993</xref>) and BALF (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). On the contrary, CD16<sup>+</sup> T cells are induced in specific conditions, such as chronic hepatitis C infection (<xref ref-type="bibr" rid="bib5">Björkström et al., 2008</xref>) and COVID-19 (<xref ref-type="bibr" rid="bib15">Georg et al., 2022</xref>). In chronic hepatitis C infection, CD16<sup>+</sup> CD8 T cells displayed a late-stage effector phenotype with high levels of perforin with a restricted TCR profile (<xref ref-type="bibr" rid="bib5">Björkström et al., 2008</xref>). Stimulation of CD16 on CD8 T cells evokes a vigorous response such as degranulation and cytokine production (IFN-γ and TNF-α) similar to that of CD16 stimulation in NK cells (<xref ref-type="bibr" rid="bib5">Björkström et al., 2008</xref>). These CD16<sup>+</sup> CD8<sup>+</sup> T cells also express a senescent marker, CD57, which differs from our findings that expanding CD16<sup>+</sup> CD8 T cells in PCP did not express CD57 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>Georg et al. recently discovered that COVID-19 severity was associated with highly activated CD16<sup>+</sup> T cells, which exhibit increased cytotoxic functions (<xref ref-type="bibr" rid="bib15">Georg et al., 2022</xref>). Although this increase was observed in CD8<sup>+</sup> T cells and not in CD4<sup>+</sup> T cells, the augmented population of CD16<sup>+</sup> T cells in BALF from patients with severe COVID-19 was further substantiated by data mining of scRNA-seq (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). CD16 expression allows T cells to degranulate and exert cytotoxicity in an immune-complex-mediated, TCR-independent manner. Moreover, CD16<sup>+</sup> T cells from COVID-19 patients caused injury to microvascular endothelial cells and induced the release of neutrophil and monocyte chemoattractants (<xref ref-type="bibr" rid="bib15">Georg et al., 2022</xref>). Georg et al. also discovered that severe COVID-19 induced increased generation of C3a, which further activates CD16<sup>+</sup> cytotoxic T cells. The proportions of activated CD16<sup>+</sup> T cells and plasma levels of complement proteins upstream of C3a were found to be associated with fatal outcomes of COVID-19, proving support for the pathological role of exacerbated cytotoxicity and complement activation in COVID-19 (<xref ref-type="bibr" rid="bib15">Georg et al., 2022</xref>). Given these findings and the observation of the highest proportion of CD16<sup>+</sup> T cells in the fatal case of PCP, we hypothesize that these CD16<sup>+</sup> T cells may possess excessive cytotoxicity toward pulmonary microvascular endothelial cells, contributing to lung injury in PCP, in addition to targeting <italic>P. jirovecii</italic>. Based on the therapeutic efficacy of an anti-complement therapy (anti-C5a antibody) for severe COVID-19 (<xref ref-type="bibr" rid="bib7">Campbell, 2020</xref>; <xref ref-type="bibr" rid="bib36">Vlaar et al., 2020</xref>), anti-complement treatments may have the potential to treat severe PCP. One of the other T cell markers correlated with the severity of PCP was CCR7, CD7, and CD57 (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), although the precise biological significance of the correlation remains to be elucidated.</p><p>We discovered an increase of CD57<sup>+</sup> CD8<sup>+</sup> T cells expressing immune checkpoints, PD-1<sup>+</sup> TIGIT<sup>+</sup> LAG3<sup>+</sup> TIM-3<sup>+</sup> in ICI-ILDs, which supports our previous findings of increased proportions of CD8<sup>+</sup> T cells positive for both PD-1 and TIM-3 or TIGIT in ICI-ILD (<xref ref-type="bibr" rid="bib31">Suzuki et al., 2020</xref>). In the ‘Materials and methods’ section, the low detection of PD-1 expression on T cells in patients treated with nivolumab was noted; this was due to the competitive nature of the PD-1 detection antibody EH12.2 with nivolumab (<xref ref-type="bibr" rid="bib38">Yanagihara et al., 2020</xref>). The absence of a metal-conjugated PD-1 antibody with the MIH4 clone presented a limitation in our study. Ideally, we would have conjugated the MIH4 antibody with 155Gd for our analysis, which is a refinement we aim to incorporate in future research. A population of PD-1<sup>+</sup> TIM-3<sup>+</sup>CD8<sup>+</sup> cells was detected in the peritumoral pleural effusion and ILD lesions of a cancer patient undergoing ICI treatment (<xref ref-type="bibr" rid="bib37">Yanagihara et al., 2017</xref>). Through the application of next-generation sequencing technology to the DNA encoding the complementarity-determining region of the T cell receptor (TCR), identical T cell clones were identified in both peritumoral pleural effusion and ILD lesions (<xref ref-type="bibr" rid="bib32">Tanaka et al., 2018</xref>). Similar to ICI-ILD, a recent study identified T cells specific to α-myosin drive ICI-related myocarditis (<xref ref-type="bibr" rid="bib4">Axelrod et al., 2022</xref>). These results indicate that ICI-activated CD8<sup>+</sup> T cells, with a phenotype of PD-1<sup>+</sup> TIGIT<sup>+</sup> LAG3<sup>+</sup> TIM-3<sup>+</sup>, could potentially trigger ILD by recognizing self-peptides or shared epitopes between tumors and lungs. CD16<sup>+</sup> CD8<sup>+</sup> T cells in PCP exhibit high CXCR3 and ST2 expression, and CD57<sup>+</sup> CD8<sup>+</sup> T cells expressing immune checkpoints in ICI-ILD express high CXCR3 (consistent with the previous study; <xref ref-type="bibr" rid="bib19">Kim et al., 2020</xref>). Therefore, these CD8<sup>+</sup> T cells could potentially migrate into the lungs via chemokines, such as CXCL4, CXCL9, CXCL10, and IL-33 (<xref ref-type="bibr" rid="bib35">Van Raemdonck et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Griesenauer and Paczesny, 2017</xref>).</p><p>Regarding CD57 expression in T cells, it is generally considered a senescent marker (<xref ref-type="bibr" rid="bib13">Fehlings et al., 2022</xref>). However, CD57<sup>+</sup> CD8<sup>+</sup> T cells in the periphery show clonal expansion with the overlap of the TCR repertoire of tumor-infiltrating T cells with favorable response to ICI in cancer patients (<xref ref-type="bibr" rid="bib13">Fehlings et al., 2022</xref>), indicating that these CD57<sup>+</sup> CD8<sup>+</sup> T cells may have a highly active phenotype in ICI-treated individuals.</p><p>FCRL5 is a B cell-restricted member of the Fc receptor-like family encoded by the <italic>IRTA2</italic> gene (<xref ref-type="bibr" rid="bib27">Rostamzadeh et al., 2018</xref>). In both rheumatoid arthritis (<xref ref-type="bibr" rid="bib23">Owczarczyk et al., 2011</xref>) and granulomatosis with polyangiitis and microscopic polyangiitis (<xref ref-type="bibr" rid="bib24">Owczarczyk et al., 2020</xref>), increased expression of FCRL5 was indicative of a positive response to rituximab. Additionally, our recent research revealed an increase in FCLR5<sup>+</sup> B cells in connective-tissue disease-related ILD (<xref ref-type="bibr" rid="bib17">Hata et al., 2023</xref>). These findings suggest a potential pathological role of FCRL5 in autoimmunity. Given that ICI-ILD is considered a type of irAE, it is reasonable to hypothesize that FCRL5<sup>+</sup> B cells may be one of the immune cells associated with autoimmunity.</p><p>Regarding myeloid cells, we found that CD14<sup>+</sup> CCR2<sup>+</sup> CCR5<sup>+</sup> monocyte subpopulations were prevalent in ICI-ILD. <xref ref-type="bibr" rid="bib14">Franken et al., 2022</xref> revealed a decrease in anti-inflammatory resident alveolar macrophages and an increase in pro-inflammatory 'M1-like' monocytes (expressing TNF, IL-1B, IL-6, IL-23A, and GM-CSF receptor CSF2RA, CSF2RB) in BALF from ICI-ILD compared with controls. Taken together with this report, the CD14<sup>+</sup> CCR2<sup>+</sup> CCR5<sup>+</sup> monocytes we found may be an M1-like monocyte.</p><p>Our study has several limitations, including the absence of data from healthy individuals, a relatively small sample size, and a retrospective design that resulted in missing clinical data for certain cases. Selection bias may also be a factor as only patients who underwent bronchoalveolar lavage were eligible for enrollment in this study. It is important to note that these findings demonstrate a correlation rather than proof of causation.</p><p>In summary, our study has shown distinct immune cell phenotypes in PCP, DI-ILD, and ICI-ILD. Specifically, we have identified an expansion of CD16<sup>+</sup> T cells in PCP, as well as an increase in CD57<sup>+</sup> CD8<sup>+</sup> T cells expressing immune checkpoints, FCRL5<sup>+</sup> B cells, and CCR2<sup>+</sup> CCR5<sup>+</sup> monocytes in ICI-ILD, which may play a pathogenic role. Based on these findings, further confirmatory research may lead to the development of diagnostic methods and novel strategies that target these specific cell populations to treat chemotherapy-induced pneumonitis.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patients</title><p>In this retrospective study, patients who were newly diagnosed with PCP, DI-ILD, and ICI-ILD and had undergone BALF collection at Kyushu University Hospital from January 2017 to April 2022 were included. The retrospective study was approved by the Ethics Committee of Kyushu University Hospital (reference number 22117-00). Patient consent was waived due to an opt-out method that was approved by the Ethics Committee of Kyushu University Hospital. Diagnostic criteria for PCP, DI-ILD, and ICI-ILD were in accordance with those previously described (<xref ref-type="bibr" rid="bib29">Skeoch et al., 2018</xref>; <xref ref-type="bibr" rid="bib3">Asai et al., 2022</xref>; <xref ref-type="bibr" rid="bib2">Apostolopoulou and Fishman, 2022</xref>; <xref ref-type="bibr" rid="bib11">Delaunay et al., 2019</xref>). A visual representation of the experimental and analytical workflow can be found in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Graphical abstract of the study.</title><p>Bronchoalveolar lavage fluid (BALF) samples were collected from patients with <italic>Pneumocystis jirovecii</italic> pneumonia (PCP), cytotoxic drug-induced interstitial lung disease (DI-ILD), and immune-checkpoint inhibitor-related ILD (ICI-ILD). Subsequently, BALF cells were analyzed using mass cytometry with a T cell panel (35 markers) and B cell/myeloid cell panel (32 markers) following CD45 barcoding for sample identification. The study found that there was a significant increase in the expansion of CD16<sup>+</sup> T cells in patients with PCP, with the highest CD16 expression observed in a fatal case of PCP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87288-fig6-v1.tif"/></fig></sec><sec id="s4-2"><title>Mass cytometry</title><p>Metal-tagged antibodies were obtained from Standard Biotools or purchased in a purified form (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) and then labeled with metals using the Maxpar Antibody Labeling Kit (Standard Biotools) as instructed by the manufacturer. The cell labeling was performed as previously described (<xref ref-type="bibr" rid="bib17">Hata et al., 2023</xref>). Upon collection, BALF samples were immediately centrifuged at 300 × <italic>g</italic> for 5 min to pellet the cells. The resultant cell pellets were then resuspended in Cellbanker 1 cryopreservation solution (Takara, Cat# 210409). This suspension was aliquoted into cryovials and gradually frozen to –80°C and stored at –80°C until required for experimental analysis. Cryopreserved BALF cells were thawed in PBS and then stained with Cell-ID Cisplatin-198Pt (Standard Biotools #201198, 1:2000 dilution) in PBS before being incubated with FcR blocking reagent (Myltenyi, #130-059-901) and barcoded with each metal-labeled CD45 antibody (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). After washing, CD45-labeled cells were mixed and stained with APC-conjugated FCRL5 antibodies (for panel #2), followed by staining with the antibody cocktail (panels #1 and #2, see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The antibody amount was determined through preliminary experiments with metal minus one. Cells were then washed, fixed with 1.6% formaldehyde, and resuspended in Cell-ID Intercalator 103Rh (Standard Biotools #201103A) in Fix and Perm buffer (Standard Biotools) at 4℃ overnight. For acquisition, cells were resuspended in MaxPar Cell Acquisition Solution (Standard Biotools #201240) containing one-fifth EQ Four Element Calibration Beads (Standard Biotools #201078) and acquired at a rate of 200–300 events/s on a Helios mass cytometer (Standard Biotools). Files were converted to FCS, randomized, and normalized for EQ bead intensity using the Helios software. Concatenating fcs files in the same group into one file was conducted by FlowJo v10.8 (BD Biosciences). Cytobank Premium (Cytobank Inc) was used to perform manual gating, visualization of t-distributed stochastic neighbor embedding (viSNE), UMAP analysis, and Citrus analysis (<xref ref-type="bibr" rid="bib6">Bruggner et al., 2014</xref>).</p></sec><sec id="s4-3"><title>Data analysis</title><p>Cisplatin-positive cells and doublets were excluded to select live cells, and CD45<sup>+</sup> cells were further analyzed. For T cells, CD2<sup>+</sup> CD3<sup>+</sup> cells were gated and subjected to UMAP and Citrus algorithms. The UMAP analysis included clustering channels for CD4, CD8a, CD27, CD28, CD45RA, CD45RO, Fas, and used the parameters: numbers of neighbors = 15, minimum distance = 0.01. The Citrus algorithm for T cells included clustering channels for CD4, CD5, CD7, CD8a, CD11a, CD16, CD27, CD28, CD44, CD45RA, CD45RO, CD49d, CD57, CD69, CD226, Fas, IL-2R, PD-L1, PD-L2, PD-1, OX40, TIGIT, TIM3, CTLA-4, CD223 (LAG-3), BTLA, ICOS, ST2, CCR7, CXCR3, HLA-DR, and used the parameters: association models = nearest shrunken centroid (PAMR), cluster characterization = abundance, minimum cluster size = 5%, cross-validation folds = 5, false discovery rate (FDR) = 1%. The Citrus analysis excluded nivolumab-induced ILD cases due to the apparent loss of PD-1 detection caused by competitive inhibition by nivolumab (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib38">Yanagihara et al., 2020</xref>). The viSNE analysis for T cells included clustering channels for CD4, CD5, CD7, CD8a, CD11a, CD16, CD27, CD28, CD44, CD45RA, CD45RO, CD49d, CD57, CD69, CD226, Fas, IL-2R, PD-L1, PD-L2, PD-1, OX40, TIGIT, TIM3, CTLA-4, CD223 (LAG-3), BTLA, ICOS, ST2, CCR7, CXCR3, and HLA-DR, and used the parameters: iterations = 1000,, perplexity = 30, theta = 0.5.</p><p>For myeloid cells, CD3<sup>–</sup> CD11b<sup>+</sup> CD11c<sup>+</sup> cells were gated, and UMAP and Citrus algorithms were used. The UMAP analysis included clustering channels for CD11b, CD11c, CD64, CD14, CD16, CD206, HLA-DR, and CCR2, and used the parameters: numbers of neighbors = 10, minimum distance = 0.01. The Citrus algorithm included clustering channels for CD11b, CD11c, CD64, CD14, CD16, CD32, CD36, CD38, CD84, CD86, CD163, CD206, CD209, CD223, HLA-DR, CCR2, CCR5, and ST2, and used the parameters: association models = nearest shrunken centroid (PAMR), cluster characterization = abundance, minimum cluster size = 5%, cross validation folds = 5, FDR = 1%. One case of PCP was excluded from the Citrus analysis due to low cell numbers.</p><p>B cells and plasma cells were identified using gating of CD3<sup>–</sup>CD64<sup>–</sup> and CD19<sup>+</sup> or CD138<sup>+</sup> cells. viSNE analysis was performed to cluster B cells using the following markers: CD19, CD38, CD11c, IgA, IgG, CD138, CD21, ST2, CXCR5, CD24, CD27, TIM-1, IgM, HLA-DR, IgD, and FCRL5. The analysis was performed on both individual and concatenated files using the parameters of 1000 iterations, perplexity of 30, and theta of 0.5.</p><p>The selection of the dimensionality reduction technique, UMAP or viSNE, was made based on their ability to retain the relationships between global structures and the distances between cell clusters (where UMAP outperformed viSNE) and their ability to present a distinct and non-overlapping portrayal of cell subpopulations, facilitating the identification of inter-group variations (where viSNE performed better than UMAP).</p></sec><sec id="s4-4"><title>Statistical analysis</title><p>We utilized a PAMR association model with a stringent threshold of 1% FDR, as described in the ‘Data analysis’ section, for the Citrus algorithm experiment. Student’s two-tailed unpaired <italic>t</italic>-test was employed to conduct a comparative analysis between the two groups. To determine the significance of serum β-<sc>d</sc>-glucan and KL-6 among three groups, a statistical analysis was performed using Kruskal–Wallis tests. We evaluated the manually gated cell proportions by performing a two-way ANOVA, along with Tukey’s multiple comparison tests. Data were analyzed using GraphPad Prism 9 software. Statistical significance was considered to be achieved when the p-value was &lt;0.05.</p></sec><sec id="s4-5"><title>Analysis of single-cell RNA sequencing data of human BALF cells</title><p>For our investigation, we utilized the publicly available dataset GSE145926, which contains single-cell RNA-sequencing data from BALF cells of both healthy controls (n = 3) and patients with severe COVID-19 (n = 6) (<xref ref-type="bibr" rid="bib20">Liao et al., 2020</xref>). We initiated our analysis by normalizing the filtered gene-barcode matrix using the ‘NormalizeData’ function in Seurat version 4, applying the default settings. Subsequently, we identified the top 2000 variable genes utilizing the ‘vst’ method available in the ‘FindVariableFeatures’ function of Seurat. Principal component analysis and UMAP were then conducted to reduce dimensionality and visualize the data. To isolate T cells for further analysis, we defined them as cells expressing <italic>CD2</italic> and <italic>CD3E</italic> with expression values greater than 1. We specifically examined the expression of <italic>FCGR3A</italic> (CD16) by setting an expression threshold of 0.5 to identify relevant cell populations. The resulting expression patterns were illustrated using violin plots and bar plots, which were generated using the ‘ggplot’ function in R.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>This research was supported by the Kakihara Foundation and Boehringer Ingelheim</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Data curation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Supervision, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Supervision, Methodology, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The retrospective study was approved by the Ethics Committee of Kyushu University Hospital (reference number 22117-00). Patient consent was waived due to an opt-out method that was approved by the Ethics Committee of Kyushu University Hospital. Diagnostic criteria for PCP, DI-ILD, and ICI-ILD were in accordance with those previously described (Skeoch et al., 2018), (Asai et al., 2022), (Apostolopoulou and Fishman, 2022), (Delaunay et al., 2019).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87288-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Mass cytometry antibody panels.</title></caption><media xlink:href="elife-87288-supp1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Raw fcs files, the case list and the code for scRNA-seq are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.2ngf1vhxd">https://doi.org/10.5061/dryad.2ngf1vhxd</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Kunimura</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Tsubouchi</surname><given-names>K</given-names></name><name><surname>Ikegame</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Fukui</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.2ngf1vhxd</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single-cell landscape of bronchoalveolar immune cells in COVID-19 patients</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926">GSE145926</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Ms. Sanae Sekihara, PhD, from Standard Biotools, for her technical assistance. We also extend our appreciation to the Medical Research Center Initiative for High Depth Omics at Kyushu University. This research was supported by the Kakihara Foundation, Boehringer Ingelheim (TY), and the Japan Agency for Medical Research and Development (YF).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis</article-title><source>Biomedicines</source><volume>9</volume><elocation-id>1484</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines9101484</pub-id><pub-id pub-id-type="pmid">34680601</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apostolopoulou</surname><given-names>A</given-names></name><name><surname>Fishman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The pathogenesis and diagnosis of <italic>Pneumocystis jiroveci</italic> Pneumonia</article-title><source>Journal of Fungi</source><volume>8</volume><elocation-id>1167</elocation-id><pub-id pub-id-type="doi">10.3390/jof8111167</pub-id><pub-id pub-id-type="pmid">36354934</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asai</surname><given-names>N</given-names></name><name><surname>Motojima</surname><given-names>S</given-names></name><name><surname>Ohkuni</surname><given-names>Y</given-names></name><name><surname>Matsunuma</surname><given-names>R</given-names></name><name><surname>Nakashita</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>N</given-names></name><name><surname>Mikamo</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia</article-title><source>Respiratory Investigation</source><volume>60</volume><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.resinv.2022.04.002</pub-id><pub-id pub-id-type="pmid">35501264</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axelrod</surname><given-names>ML</given-names></name><name><surname>Meijers</surname><given-names>WC</given-names></name><name><surname>Screever</surname><given-names>EM</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>MG</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Tannous</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sugiura</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>BC</given-names></name><name><surname>Hanna</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Amancherla</surname><given-names>K</given-names></name><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Wright</surname><given-names>JJ</given-names></name><name><surname>Wei</surname><given-names>SC</given-names></name><name><surname>Opalenik</surname><given-names>SR</given-names></name><name><surname>Toren</surname><given-names>AL</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name><name><surname>Ferrell</surname><given-names>PB</given-names></name><name><surname>Phillips</surname><given-names>EJ</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>DB</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Moslehi</surname><given-names>JJ</given-names></name><name><surname>Balko</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>T cells specific for α-myosin drive immunotherapy-related myocarditis</article-title><source>Nature</source><volume>611</volume><fpage>818</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05432-3</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Björkström</surname><given-names>NK</given-names></name><name><surname>Gonzalez</surname><given-names>VD</given-names></name><name><surname>Malmberg</surname><given-names>K-J</given-names></name><name><surname>Falconer</surname><given-names>K</given-names></name><name><surname>Alaeus</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>G</given-names></name><name><surname>Jorns</surname><given-names>C</given-names></name><name><surname>Ericzon</surname><given-names>B-G</given-names></name><name><surname>Weiland</surname><given-names>O</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>4219</fpage><lpage>4228</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.6.4219</pub-id><pub-id pub-id-type="pmid">18768879</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruggner</surname><given-names>RV</given-names></name><name><surname>Bodenmiller</surname><given-names>B</given-names></name><name><surname>Dill</surname><given-names>DL</given-names></name><name><surname>Tibshirani</surname><given-names>RJ</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Automated identification of stratifying signatures in cellular subpopulations</article-title><source>PNAS</source><volume>111</volume><fpage>E2770</fpage><lpage>E2777</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408792111</pub-id><pub-id pub-id-type="pmid">24979804</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The opening salvo of anti-complement therapy against COVID-19</article-title><source>The Lancet. Rheumatology</source><volume>2</volume><fpage>e729</fpage><lpage>e730</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30353-2</pub-id><pub-id pub-id-type="pmid">33015642</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chedid</surname><given-names>C</given-names></name><name><surname>Andrieu</surname><given-names>T</given-names></name><name><surname>Kokhreidze</surname><given-names>E</given-names></name><name><surname>Tukvadze</surname><given-names>N</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Ather</surname><given-names>MF</given-names></name><name><surname>Uddin</surname><given-names>MKM</given-names></name><name><surname>Banu</surname><given-names>S</given-names></name><name><surname>De Maio</surname><given-names>F</given-names></name><name><surname>Delogu</surname><given-names>G</given-names></name><name><surname>Endtz</surname><given-names>H</given-names></name><name><surname>Goletti</surname><given-names>D</given-names></name><name><surname>Vocanson</surname><given-names>M</given-names></name><name><surname>Dumitrescu</surname><given-names>O</given-names></name><name><surname>Hoffmann</surname><given-names>J</given-names></name><name><surname>Ader</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>In-Depth Immunophenotyping with mass cytometry durintreatment reveals newg TB treatment reveals new T-cell subsets associated with culture conversion</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>853572</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.853572</pub-id><pub-id pub-id-type="pmid">35392094</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conte</surname><given-names>P</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Patelli</surname><given-names>G</given-names></name><name><surname>Danesi</surname><given-names>R</given-names></name><name><surname>Vanzulli</surname><given-names>A</given-names></name><name><surname>Sandomenico</surname><given-names>F</given-names></name><name><surname>Tarsia</surname><given-names>P</given-names></name><name><surname>Cattelan</surname><given-names>A</given-names></name><name><surname>Comes</surname><given-names>A</given-names></name><name><surname>De Laurentiis</surname><given-names>M</given-names></name><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Regge</surname><given-names>D</given-names></name><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment</article-title><source>ESMO Open</source><volume>7</volume><elocation-id>100404</elocation-id><pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100404</pub-id><pub-id pub-id-type="pmid">35219244</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couloume</surname><given-names>L</given-names></name><name><surname>Ferrant</surname><given-names>J</given-names></name><name><surname>Le Gallou</surname><given-names>S</given-names></name><name><surname>Mandon</surname><given-names>M</given-names></name><name><surname>Jean</surname><given-names>R</given-names></name><name><surname>Bescher</surname><given-names>N</given-names></name><name><surname>Zephir</surname><given-names>H</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Thouvenot</surname><given-names>E</given-names></name><name><surname>Ruet</surname><given-names>A</given-names></name><name><surname>Debouverie</surname><given-names>M</given-names></name><name><surname>Tarte</surname><given-names>K</given-names></name><name><surname>Amé</surname><given-names>P</given-names></name><name><surname>Roussel</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mass cytometry identifies expansion of T-bet+ B Cells and CD206+ monocytes in early multiple sclerosis</article-title><source>Frontiers in Immunology</source><volume>12</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.653577</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaunay</surname><given-names>M</given-names></name><name><surname>Prévot</surname><given-names>G</given-names></name><name><surname>Collot</surname><given-names>S</given-names></name><name><surname>Guilleminault</surname><given-names>L</given-names></name><name><surname>Didier</surname><given-names>A</given-names></name><name><surname>Mazières</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Management of pulmonary toxicity associated with immune checkpoint inhibitors</article-title><source>European Respiratory Review</source><volume>28</volume><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1183/16000617.0012-2019</pub-id><pub-id pub-id-type="pmid">31694838</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dement-Brown</surname><given-names>J</given-names></name><name><surname>Newton</surname><given-names>CS</given-names></name><name><surname>Ise</surname><given-names>T</given-names></name><name><surname>Damdinsuren</surname><given-names>B</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Tolnay</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes</article-title><source>Journal of Leukocyte Biology</source><volume>91</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1189/jlb.0211096</pub-id><pub-id pub-id-type="pmid">22028333</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehlings</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Yuen</surname><given-names>K</given-names></name><name><surname>Tafazzol</surname><given-names>A</given-names></name><name><surname>Sanjabi</surname><given-names>S</given-names></name><name><surname>Zill</surname><given-names>OA</given-names></name><name><surname>Rishipathak</surname><given-names>D</given-names></name><name><surname>Wallace</surname><given-names>A</given-names></name><name><surname>Nardin</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Milojkovic</surname><given-names>A</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell analysis reveals clonally expanded tumor-associated CD57<sup>+</sup> CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade</article-title><source>Journal for Immunotherapy of Cancer</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1136/jitc-2022-004759</pub-id><pub-id pub-id-type="pmid">35981786</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franken</surname><given-names>A</given-names></name><name><surname>Van Mol</surname><given-names>P</given-names></name><name><surname>Vanmassenhove</surname><given-names>S</given-names></name><name><surname>Donders</surname><given-names>E</given-names></name><name><surname>Schepers</surname><given-names>R</given-names></name><name><surname>Van Brussel</surname><given-names>T</given-names></name><name><surname>Dooms</surname><given-names>C</given-names></name><name><surname>Yserbyt</surname><given-names>J</given-names></name><name><surname>De Crem</surname><given-names>N</given-names></name><name><surname>Testelmans</surname><given-names>D</given-names></name><name><surname>De Wever</surname><given-names>W</given-names></name><name><surname>Nackaerts</surname><given-names>K</given-names></name><name><surname>Vansteenkiste</surname><given-names>J</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Humblet-Baron</surname><given-names>S</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Wauters</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis</article-title><source>Journal for Immunotherapy of Cancer</source><volume>10</volume><elocation-id>e005323</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2022-005323</pub-id><pub-id pub-id-type="pmid">36171010</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georg</surname><given-names>P</given-names></name><name><surname>Astaburuaga-García</surname><given-names>R</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>Brumhard</surname><given-names>S</given-names></name><name><surname>Michalick</surname><given-names>L</given-names></name><name><surname>Lippert</surname><given-names>LJ</given-names></name><name><surname>Kostevc</surname><given-names>T</given-names></name><name><surname>Gäbel</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Streitz</surname><given-names>M</given-names></name><name><surname>Demichev</surname><given-names>V</given-names></name><name><surname>Gemünd</surname><given-names>I</given-names></name><name><surname>Barone</surname><given-names>M</given-names></name><name><surname>Tober-Lau</surname><given-names>P</given-names></name><name><surname>Helbig</surname><given-names>ET</given-names></name><name><surname>Hillus</surname><given-names>D</given-names></name><name><surname>Petrov</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Dey</surname><given-names>HP</given-names></name><name><surname>Paclik</surname><given-names>D</given-names></name><name><surname>Iwert</surname><given-names>C</given-names></name><name><surname>Mülleder</surname><given-names>M</given-names></name><name><surname>Aulakh</surname><given-names>SK</given-names></name><name><surname>Djudjaj</surname><given-names>S</given-names></name><name><surname>Bülow</surname><given-names>RD</given-names></name><name><surname>Mei</surname><given-names>HE</given-names></name><name><surname>Schulz</surname><given-names>AR</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Saliba</surname><given-names>AE</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Lehmann</surname><given-names>I</given-names></name><name><surname>Mall</surname><given-names>MA</given-names></name><name><surname>Stricker</surname><given-names>S</given-names></name><name><surname>Röhmel</surname><given-names>J</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Beule</surname><given-names>D</given-names></name><name><surname>Wyler</surname><given-names>E</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Obermayer</surname><given-names>B</given-names></name><name><surname>von Stillfried</surname><given-names>S</given-names></name><name><surname>Boor</surname><given-names>P</given-names></name><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Wesselmann</surname><given-names>H</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>Uhrig</surname><given-names>A</given-names></name><name><surname>Müller-Redetzky</surname><given-names>H</given-names></name><name><surname>Nattermann</surname><given-names>J</given-names></name><name><surname>Kuebler</surname><given-names>WM</given-names></name><name><surname>Meisel</surname><given-names>C</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Thibeault</surname><given-names>C</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Blüthgen</surname><given-names>N</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><collab>PA-COVID-19 Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Complement activation induces excessive T cell cytotoxicity in severe COVID-19</article-title><source>Cell</source><volume>185</volume><fpage>493</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.040</pub-id><pub-id pub-id-type="pmid">35032429</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesenauer</surname><given-names>B</given-names></name><name><surname>Paczesny</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The ST2/IL-33 axis in immune cells during inflammatory diseases</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>475</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00475</pub-id><pub-id pub-id-type="pmid">28484466</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Kunimura</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Tsubouchi</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>D</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Uehara</surname><given-names>M</given-names></name><name><surname>Ikegame</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Fukui</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1145814</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1145814</pub-id><pub-id pub-id-type="pmid">36949950</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Kohno</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases</article-title><source>Respiratory Investigation</source><volume>50</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.resinv.2012.02.001</pub-id><pub-id pub-id-type="pmid">22554854</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Sheshadri</surname><given-names>A</given-names></name><name><surname>Shannon</surname><given-names>V</given-names></name><name><surname>Kontoyiannis</surname><given-names>DP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Im</surname><given-names>JS</given-names></name><name><surname>Boddu</surname><given-names>P</given-names></name><name><surname>Bashoura</surname><given-names>L</given-names></name><name><surname>Balachandran</surname><given-names>DD</given-names></name><name><surname>Evans</surname><given-names>SE</given-names></name><name><surname>Faiz</surname><given-names>S</given-names></name><name><surname>Ruiz Vazquez</surname><given-names>W</given-names></name><name><surname>Divenko</surname><given-names>M</given-names></name><name><surname>Mathur</surname><given-names>R</given-names></name><name><surname>Tippen</surname><given-names>SP</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Neelapu</surname><given-names>SS</given-names></name><name><surname>Naing</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Diab</surname><given-names>A</given-names></name><name><surname>Futreal</surname><given-names>A</given-names></name><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Daver</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct immunophenotypes of t cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>590494</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.590494</pub-id><pub-id pub-id-type="pmid">33552049</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Kunimura</surname><given-names>K</given-names></name><name><surname>Yamane</surname><given-names>N</given-names></name><name><surname>Aihara</surname><given-names>R</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Sakata</surname><given-names>D</given-names></name><name><surname>Uruno</surname><given-names>T</given-names></name><name><surname>Fukui</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DOCK8 deficiency causes a skewing to type 2 immunity in the gut with expansion of group 2 innate lymphoid cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>559</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.04.094</pub-id><pub-id pub-id-type="pmid">33940384</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Redelman-Sidi</surname><given-names>G</given-names></name><name><surname>Elkington</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy</article-title><source>Thorax</source><volume>77</volume><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2021-217260</pub-id><pub-id pub-id-type="pmid">34607905</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owczarczyk</surname><given-names>K</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Abbas</surname><given-names>AR</given-names></name><name><surname>Wolslegel</surname><given-names>K</given-names></name><name><surname>Holweg</surname><given-names>CTJ</given-names></name><name><surname>Dummer</surname><given-names>W</given-names></name><name><surname>Kelman</surname><given-names>A</given-names></name><name><surname>Brunetta</surname><given-names>P</given-names></name><name><surname>Lewin-Koh</surname><given-names>N</given-names></name><name><surname>Sorani</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>D</given-names></name><name><surname>Fielder</surname><given-names>P</given-names></name><name><surname>Yocum</surname><given-names>D</given-names></name><name><surname>Ho</surname><given-names>C</given-names></name><name><surname>Ortmann</surname><given-names>W</given-names></name><name><surname>Townsend</surname><given-names>MJ</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis</article-title><source>Science Translational Medicine</source><volume>3</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002432</pub-id><pub-id pub-id-type="pmid">21937757</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owczarczyk</surname><given-names>K</given-names></name><name><surname>Cascino</surname><given-names>MD</given-names></name><name><surname>Holweg</surname><given-names>C</given-names></name><name><surname>Tew</surname><given-names>GW</given-names></name><name><surname>Ortmann</surname><given-names>W</given-names></name><name><surname>Behrens</surname><given-names>T</given-names></name><name><surname>Schindler</surname><given-names>T</given-names></name><name><surname>Langford</surname><given-names>CA</given-names></name><name><surname>St Clair</surname><given-names>EW</given-names></name><name><surname>Merkel</surname><given-names>PA</given-names></name><name><surname>Spiera</surname><given-names>R</given-names></name><name><surname>Seo</surname><given-names>P</given-names></name><name><surname>Kallenberg</surname><given-names>CG</given-names></name><name><surname>Specks</surname><given-names>U</given-names></name><name><surname>Lim</surname><given-names>N</given-names></name><name><surname>Stone</surname><given-names>J</given-names></name><name><surname>Brunetta</surname><given-names>P</given-names></name><name><surname>Prunotto</surname><given-names>M</given-names></name><collab>RAVE-ITN Research Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e136180</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136180</pub-id><pub-id pub-id-type="pmid">32841219</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Sidlow</surname><given-names>R</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Immune-related adverse events associated with immune checkpoint blockade</article-title><source>The New England Journal of Medicine</source><volume>378</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1703481</pub-id><pub-id pub-id-type="pmid">29320654</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Bolland</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>IgG Fc receptors</article-title><source>Annual Review of Immunology</source><volume>19</volume><fpage>275</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.275</pub-id><pub-id pub-id-type="pmid">11244038</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostamzadeh</surname><given-names>D</given-names></name><name><surname>Kazemi</surname><given-names>T</given-names></name><name><surname>Amirghofran</surname><given-names>Z</given-names></name><name><surname>Shabani</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>22</volume><fpage>487</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1080/14728222.2018.1472768</pub-id><pub-id pub-id-type="pmid">29737217</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandor</surname><given-names>M</given-names></name><name><surname>Lynch</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Lymphocyte Fc receptors: the special case of T cells</article-title><source>Immunology Today</source><volume>14</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(93)90168-K</pub-id><pub-id pub-id-type="pmid">8517922</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skeoch</surname><given-names>S</given-names></name><name><surname>Weatherley</surname><given-names>N</given-names></name><name><surname>Swift</surname><given-names>AJ</given-names></name><name><surname>Oldroyd</surname><given-names>A</given-names></name><name><surname>Johns</surname><given-names>C</given-names></name><name><surname>Hayton</surname><given-names>C</given-names></name><name><surname>Giollo</surname><given-names>A</given-names></name><name><surname>Wild</surname><given-names>JM</given-names></name><name><surname>Waterton</surname><given-names>JC</given-names></name><name><surname>Buch</surname><given-names>M</given-names></name><name><surname>Linton</surname><given-names>K</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Chaudhuri</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Drug-Induced interstitial lung disease: a systematic review</article-title><source>Journal of Clinical Medicine</source><volume>7</volume><elocation-id>356</elocation-id><pub-id pub-id-type="doi">10.3390/jcm7100356</pub-id><pub-id pub-id-type="pmid">30326612</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>MH</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mass cytometry: single cells, many features</article-title><source>Cell</source><volume>165</volume><fpage>780</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.019</pub-id><pub-id pub-id-type="pmid">27153492</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Kusaba</surname><given-names>H</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Ikematsu</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Otsubo</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Yoneshima</surname><given-names>Y</given-names></name><name><surname>Iwama</surname><given-names>E</given-names></name><name><surname>Arimura-Omori</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>E</given-names></name><name><surname>Hamada</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease</article-title><source>International Immunology</source><volume>32</volume><fpage>547</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxaa022</pub-id><pub-id pub-id-type="pmid">32253426</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Ikematsu</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Ota</surname><given-names>K</given-names></name><name><surname>Kashiwagi</surname><given-names>E</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Hamada</surname><given-names>N</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Tatsugami</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Ijichi</surname><given-names>K</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Otsubo</surname><given-names>K</given-names></name><name><surname>Yoneshima</surname><given-names>Y</given-names></name><name><surname>Iwama</surname><given-names>E</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade</article-title><source>Oncotarget</source><volume>9</volume><fpage>30587</fpage><lpage>30593</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25743</pub-id><pub-id pub-id-type="pmid">30093971</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasaka</surname><given-names>S</given-names></name><name><surname>Hasegawa</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>W</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Ishizaka</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Serum indicators for the diagnosis of pneumocystis pneumonia</article-title><source>Chest</source><volume>131</volume><fpage>1173</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1378/chest.06-1467</pub-id><pub-id pub-id-type="pmid">17426225</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>CF</given-names></name><name><surname>Limper</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Pneumocystis pneumonia</article-title><source>The New England Journal of Medicine</source><volume>350</volume><fpage>2487</fpage><lpage>2498</lpage><pub-id pub-id-type="doi">10.1056/NEJMra032588</pub-id><pub-id pub-id-type="pmid">15190141</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Raemdonck</surname><given-names>K</given-names></name><name><surname>Van den Steen</surname><given-names>PE</given-names></name><name><surname>Liekens</surname><given-names>S</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CXCR3 ligands in disease and therapy</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>26</volume><fpage>311</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.11.009</pub-id><pub-id pub-id-type="pmid">25498524</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlaar</surname><given-names>APJ</given-names></name><name><surname>de Bruin</surname><given-names>S</given-names></name><name><surname>Busch</surname><given-names>M</given-names></name><name><surname>Timmermans</surname><given-names>S</given-names></name><name><surname>van</surname><given-names>IE</given-names></name><name><surname>Koning</surname><given-names>R</given-names></name><name><surname>Horst</surname><given-names>L</given-names></name><name><surname>Bulle</surname><given-names>EB</given-names></name><name><surname>van</surname><given-names>F</given-names></name><name><surname>Poll</surname><given-names>MCG</given-names></name><name><surname>Kemper</surname><given-names>EM</given-names></name><name><surname>Horst</surname><given-names>ICC</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name><name><surname>Horn</surname><given-names>J</given-names></name><name><surname>Paulus</surname><given-names>F</given-names></name><name><surname>Bos</surname><given-names>LD</given-names></name><name><surname>Wiersinga</surname><given-names>WJ</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Rueckinger</surname><given-names>S</given-names></name><name><surname>Pilz</surname><given-names>K</given-names></name><name><surname>Brouwer</surname><given-names>MC</given-names></name><name><surname>Guo</surname><given-names>RF</given-names></name><name><surname>Heunks</surname><given-names>L</given-names></name><name><surname>Paassen</surname><given-names>P</given-names></name><name><surname>Riedemann</surname><given-names>NC</given-names></name><name><surname>van de</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. 2</article-title><source>Lancet Rheumatol</source><volume>2</volume><fpage>COVID</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30341-6</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Ota</surname><given-names>K</given-names></name><name><surname>Kashiwagi</surname><given-names>E</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Tatsugami</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment</article-title><source>Annals of Oncology</source><volume>28</volume><fpage>2038</fpage><lpage>2039</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx214</pub-id><pub-id pub-id-type="pmid">28459940</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A measuring method for occupancy of immune checkpoint inhibitors in the cell surface</article-title><source>Biochemical and Biophysical Research Communications</source><volume>527</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.04.122</pub-id><pub-id pub-id-type="pmid">32446369</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87288.4.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Tony</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>King's College London</institution><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study presents a <bold>valuable</bold> inventory of immune signatures that are correlated with cancer treatment-related pneumonitis. The data were collected and analyzed using validated methodology and can be used as a starting point for further prospective studies. The authors have provided an scRNA-seq analysis with an HD baseline using publicly available dataset and the evidence for their claims is <bold>convincing</bold>.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87288.4.sa1</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Yanagihara and colleagues investigated the immune cell composition of bronchoalveolar lavage fluid (BALF) samples in a cohort of patients with malignancy undergoing chemotherapy and with lung adverse reactions including Pneumocystis jirovecii pneumonia (PCP) and immune-checkpoint inhibitors (ICIs) or cytotoxic drug induced interstitial lung diseases (ILDs). Using mass cytometry, their aim was to characterize the cellular and molecular changes in BAL to improve our understanding of their pathogenesis and identify potential biomarkers and therapeutic targets. In this regard, the authors identify a correlation between CD16 expression in T cells and the severity of PCP and an increased infiltration of CD57+ CD8+ T cells expressing immune checkpoints and FCLR5+ B cells in ICI-ILD patients.</p><p>The conclusions of this paper are mostly well supported by data, but some aspects of the data analysis need to be clarified and extended.</p><p>The authors should elaborate on why different sets of markers were selected for each analysis step. E.g., Different sets of markers were used for UMAP, CITRUS and viSNE in the T cell and myeloid analysis.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87288.4.sa2</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors collected BALF samples from lung cancer patients newly diagnosed with PCP, DI-ILD or ICI-ILD. CyTOF was performed on these samples, using two different panels (T-cell and B-cell/myeloid cell panels). Results were collected, cleaned-up, manually gated and pre-processed prior to visualisation with manifold learning approaches t-SNE (in the form of viSNE) or UMAP, and analysed by CITRUS (hierarchical clustering followed by feature selection and regression) for population identification - all using Cytobank implementation - in an attempt to identify possible biomarkers for these disease states. By comparing cell abundances from CITRUS results and qualitative inspection of a small number of marker expressions, the authors claimed to have identified an expansion of CD16+ T-cell population in PCP cases and an increase in CD57+ CD8+ T-cells, FCRL5+ B-cells and CCR2+ CCR5+ CD14+ monocytes in ICI-ILD cases.</p><p>By the authors' own admission, there is an absence of healthy donor samples and, perhaps as a result of retrospective experimental design and practical clinical reasons, also an absence of pre-treatment samples. The entire analysis effectively compares three yet-established disease states with no common baseline - what really constitutes a &quot;biomarker&quot; in such cases? These are very limited comparisons among three, and only these three, states.</p><p>By including a new scRNA-Seq analysis using a publicly available dataset, the authors addressed this fundamental problem. Though a more thorough and numerical analysis would be appreciated for a deeper and more impactful analysis, this is adequate for the intended objectives of the study.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87288.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yanagihara</surname><given-names>Toyoshi</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hata</surname><given-names>Kentaro</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Matsubara</surname><given-names>Keisuke</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kunimura</surname><given-names>Kazufumi</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Kunihiro</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Tsubouchi</surname><given-names>Kazuya</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ikegame</surname><given-names>Satoshi</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Baba</surname><given-names>Yoshihiro</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Fukui</surname><given-names>Yoshinori</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Okamoto</surname><given-names>Isamu</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This study presents a useful inventory of immune signatures that are correlated with cancer treatment-related pneumonitis. The data were collected and analysed using solid and validated methodology and can be used as a starting point for further functional studies.</p></disp-quote><p>We sincerely thank the editor for their encouraging comments regarding our study. As rightly pointed out, this study indeed serves as a pivotal starting point for subsequent functional studies.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>I greatly appreciate the authors diligence in addressing all the suggested points. The paper now presents significantly stronger evidence to support the findings.</p><p>I do have one final question: Could you clarify how the correlation presented in Supplementary Figure 3 was calculated? Is it a Pearson correlation of CTCAE grade directly to marker expression? Additionally, could you explain how the significance was determined? The authors mention a significant correlation for CCR7, but the heatmap displays similarly high values for CD7 and CD57. Finally, I'm curious about the absence of CD16 in the heatmap.</p></disp-quote><p>Thank you for your insightful query. To clarify, the correlation shown in Supplementary Figure 3 was indeed calculated using the Pearson correlation coefficient. This involved correlating the CTCAE grade directly with the mean expression levels of each marker. The computations were conducted using GraphPad Prism version 9. Regarding the statistical significance, we defined a threshold of P &lt; 0.05 as significant. Specifically, the P-values for CCR7, CD7, and CD57 were found to be 0.009, 0.035, and 0.039, respectively. Hence, while CCR7 showed a significant correlation, CD7 and CD57 also exhibited relatively high values, as correctly observed. We have added CD7 and CD57 along with CCR7 in the discussion section, though not to mention much for better focusing on CD16.</p><p>CD16 was initially omitted from Supplementary Figure 3 to prevent redundancy and preserve data clarity. Nonetheless, in light of your query, we have included CD16 in the correlation matrix to provide a comprehensive view of its association with other markers.</p><p>We hope this adequately addresses your question and further clarifies our findings.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>General suggestions for presentation in the future:</p><p>It is essential to concretely define the numbers presented in all figures and plots. For example, in Figure 6 (I), what does it mean by &quot;percentage representation of FCGR3A (CD16)&quot;? Percentage of what? How did you calculate that? It is also important to show more statistics in general, for example, in dot plots like Figure 6 (H), where are the means and p-values? Little things like that completely change the impact of the figures. For the narrative of this paper, it is OK, but in the future, fine-tuning the presentation would massively improve the impact of the work which the contents deserve.</p></disp-quote><p>Thank you for your insightful feedback. Addressing your concerns, I have revised Figure 6H and Figure 6I to provide a more precise and informative presentation of our data. In Figure 6H, the violin plots illustrate the expression intensity of FCGR3A (CD16) on CD4+ and CD8+ T cells. Each dot represents an individual cell within the BALF from both healthy controls (HC) and COVID-19 patients. This data was derived from the single-cell RNA-seq dataset GSE145926. To enhance clarity and statistical robustness, I have now included p-values directly in Figure 6H. Additionally, for a more comprehensive understanding, the means ± standard deviation (SD) have been incorporated into the main text of the manuscript.</p><p>Regarding Figure 6I, it depicts the proportion of FCGR3A (CD16)-positive cells within the CD4+ and CD8+ T cell populations in BALF from HC and COVID-19 patients. The threshold for FCGR3A expression was set at 0.5. Upon further review and in response to your feedback, I realized an error in the calculation of the proportion of FCGR3A-positive cells among CD4+ and CD8+ T cells. Initially, the proportion of FCGR3A-positive CD4+ T cells was calculated in relation to the entire CD4+ T cell population, without differentiation between the groups. This has now been corrected, and the adjusted figures are presented in Figure 6I.</p><p>I am grateful for the opportunity to refine these figures, as your suggestions have not only helped to correct the error but have also significantly enhanced the impact and clarity of our work. Your guidance has been instrumental in improving the overall quality and presentation of our research, ensuring that the findings are communicated effectively and accurately.</p></body></sub-article></article>